Concepedia

K. Mross

KM

Statistics

Publications

92

Citations

5.8K

H-Index

37

Active since

1986

Affiliations

University of Freiburg(Current)

University Medical Center Freiburg

Universität Hamburg

University Medical Center Hamburg-Eppendorf

Bayer (Germany)

K. Mross is an author at University of Freiburg specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

1986–2020

92

Publications

92

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text

, , +16

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 333 citations

, , +17

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

, , +17

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

, , +16

Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer

Nicolaus Kröger, Ulrich R. Kleeberg, K. Mross et al. · Oncology Research and Treatment · 2000 · 208 citations

, , +15

1–5 of 92